119 related articles for article (PubMed ID: 30694565)
1. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
Novoplansky O; Fury M; Prasad M; Yegodayev K; Zorea J; Cohen L; Pelossof R; Cohen L; Katabi N; Cecchi F; Joshua BZ; Popovtzer A; Baselga J; Scaltriti M; Elkabets M
Int J Cancer; 2019 Aug; 145(3):748-762. PubMed ID: 30694565
[TBL] [Abstract][Full Text] [Related]
2. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
[TBL] [Abstract][Full Text] [Related]
3. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
[TBL] [Abstract][Full Text] [Related]
4. SOX18 meditates the resistance of Bmi1-expressing cells to cetuximab in HNSCC.
Zhang C; Chen Z; Gao N; Xiong G; Chen P; Li H; Chen D; He Q; Peng L
Oral Dis; 2024 Apr; 30(3):1100-1113. PubMed ID: 37184032
[TBL] [Abstract][Full Text] [Related]
5. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
[TBL] [Abstract][Full Text] [Related]
6. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
Iida M; McDaniel NK; Kostecki KL; Welke NB; Kranjac CA; Liu P; Longhurst C; Bruce JY; Hong S; Salgia R; Wheeler DL
BMC Cancer; 2022 Apr; 22(1):447. PubMed ID: 35461210
[TBL] [Abstract][Full Text] [Related]
7. Multi-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma.
Ludwig ML; Michmerhuizen NL; Wang J; Birkeland AC; Majchrowski BK; Nimmagadda S; Zhai J; Bhangale A; Kulkarni A; Jiang H; Swiecicki PL; Brenner JC
Arch Oral Biol; 2023 Dec; 156():105822. PubMed ID: 37844343
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines.
Gomes INF; da Silva-Oliveira RJ; da Silva LS; Martinho O; Evangelista AF; van Helvoort Lengert A; Leal LF; Silva VAO; Dos Santos SP; Nascimento FC; Lopes Carvalho A; Reis RM
Cells; 2022 Jan; 11(1):. PubMed ID: 35011716
[TBL] [Abstract][Full Text] [Related]
9. miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC.
Citron F; Segatto I; Musco L; Pellarin I; Rampioni Vinciguerra GL; Franchin G; Fanetti G; Miccichè F; Giacomarra V; Lupato V; Favero A; Concina I; Srinivasan S; Avanzo M; Castiglioni I; Barzan L; Sulfaro S; Petrone G; Viale A; Draetta GF; Vecchione A; Belletti B; Baldassarre G
EMBO Mol Med; 2021 Jul; 13(7):e12872. PubMed ID: 34062049
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review).
Diniz CHP; Henrique T; Stefanini ACB; De Castro TB; Tajara EH
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38639184
[TBL] [Abstract][Full Text] [Related]
11. Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.
Zaryouh H; De Pauw I; Baysal H; Melis J; Van den Bossche V; Hermans C; Lau HW; Lambrechts H; Merlin C; Corbet C; Peeters M; Vermorken JB; De Waele J; Lardon F; Wouters A
Cancer Drug Resist; 2023; 6(4):709-728. PubMed ID: 38239393
[No Abstract] [Full Text] [Related]
12. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
13. Head and neck squamous cell carcinoma.
Johnson DE; Burtness B; Leemans CR; Lui VWY; Bauman JE; Grandis JR
Nat Rev Dis Primers; 2020 Nov; 6(1):92. PubMed ID: 33243986
[TBL] [Abstract][Full Text] [Related]
14. Clinical update on head and neck cancer: molecular biology and ongoing challenges.
Alsahafi E; Begg K; Amelio I; Raulf N; Lucarelli P; Sauter T; Tavassoli M
Cell Death Dis; 2019 Jul; 10(8):540. PubMed ID: 31308358
[TBL] [Abstract][Full Text] [Related]
15. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Badarni M; Prasad M; Balaban N; Zorea J; Yegodayev KM; Joshua BZ; Dinur AB; Grénman R; Rotblat B; Cohen L; Elkabets M
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30860495
[TBL] [Abstract][Full Text] [Related]
16. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.
Kong LR; Mohamed Salleh NAB; Ong RW; Tan TZ; Syn NL; Goh RM; Fhu CW; Tan DSW; Iyer NG; Kannan S; Verma CS; Lim YC; Soo R; Ho J; Huang Y; Lim JSJ; Yan BJ; Nga ME; Lim SG; Koeffler HP; Lee SC; Kappei D; Hung HT; Goh BC
Nat Commun; 2020 Mar; 11(1):1556. PubMed ID: 32214092
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance in head and neck cancer.
Picon H; Guddati AK
Am J Cancer Res; 2020; 10(9):2742-2751. PubMed ID: 33042614
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
Ma YX; Liu FR; Zhang Y; Chen Q; Chen ZQ; Liu QW; Huang Y; Yang YP; Fang WF; Xi N; Kang N; Zhuang YL; Zhang Q; Jiang YZ; Zhang L; Zhao HY
Front Immunol; 2022; 13():1024755. PubMed ID: 36341335
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.
Raj S; Kesari KK; Kumar A; Rathi B; Sharma A; Gupta PK; Jha SK; Jha NK; Slama P; Roychoudhury S; Kumar D
Mol Cancer; 2022 Jan; 21(1):31. PubMed ID: 35081970
[TBL] [Abstract][Full Text] [Related]
20. Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.
Burgy M; Jehl A; Conrad O; Foppolo S; Bruban V; Etienne-Selloum N; Jung AC; Masson M; Macabre C; Ledrappier S; Burckel H; Mura C; Noël G; Borel C; Fasquelle F; Onea MA; Chenard MP; Thiéry A; Dontenwill M; Martin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
